September 2022

Investigators recommend that genomic testing be adopted to be a reflexive and natural step in evaluating patients with non–small cell lung cancer and colorectal cancer/

The bispecific antibodies for B-cell lymphoma that are under development target CD20, and they have a second receptor that targets CD3, which is present on vector T cells, according to Loretta J. Nastoupil, MD.

Targeted Therapies in Oncology asked some experts in prostate cancer diagnostics and therapeutics for their thoughts on the milestone improvements in treating patients with prostate cancer over the past decade.

Clinicians use their knowledge of emerging subtypes and biomarkers, which provide a hint at possible outcomes, to select therapy from among the ever-increasing treatment armamentarium.

Emerging from a 2-year pandemic, the work-from-home revolution has led to the migration of staff to the pharmaceutical industry or contract research organizations.

Results from the SUMMIT basket study revealed encouraging results with a neratinib triplet regimen in patients with HR-positive/ HER2-negative metastatic breast cancer compared with other variations and monotherapies of the 3 drugs.

Positive findings were reported from the phase 2 ARNEO trial during the European Association of Urology Congress 2022.

The combination of toripalimab and chemotherapy displayed promising efficacy results in a phase 2 study.

Adjuvant pembrolizumab continues to demonstrate these impressive results with disease-free survival in renal cell carcinoma, according to Thomas Powles, MD, MBBS, MRCP.

Doctors and patients who can stick with a regimen despite relatively minor adverse event will ultimately have more options later in the treatment journey, which could then lead to better long-term outcomes in chronic lymphocytic leukemia.